Paper Details

  1. Home
  2. Paper Details

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Author: Bueso-RamosCarlos, CortesJorge, DavisJan, EstrovZeev, FaderlStefan, FerrajoliAlessandra, Garcia-ManeroGuillermo, GilesFrancis, HuangXuelin, IssaJean-Pierre J, KantarjianHagop, O'BrienSusan, OkiYasuhiro, RavandiFarhad, SabaHussain I, ShanJianqin, WierdaWilliam

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study investigated the clinical and pharmacodynamic results of different dose schedules of decitabine in patients with myelodysplastic syndrome (MDS). A high dose-intensity schedule of decitabine was found to optimize epigenetic modulation and clinical responses in MDS.
Paper Details　
Original Abstract of the Article :
Epigenetic therapy with hypomethylating drugs is now the standard of care in myelodysplastic syndrome (MDS). Response rates remain low, and mechanism-based dose optimization has not been reported. We investigated the clinical and pharmacodynamic results of different dose schedules of decitabine. Adu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1182/blood-2006-05-021162

データ提供：米国国立医学図書館（NLM）

Epigenetic Therapy: Navigating the Shifting Sands of MDS Treatment

The field of epigenetics is revolutionizing our understanding of disease, particularly in cancers like myelodysplastic syndrome (MDS). This research explores the potential of epigenetic therapy with hypomethylating drugs, like decitabine, in treating MDS. The authors examine the impact of different dose schedules of decitabine on clinical outcomes and pharmacodynamic effects, aiming to optimize treatment strategies for this challenging disease.

The Quest for Optimal Dose: Finding the Right Path in the Desert of MDS Treatment

This research reveals the complex relationship between dose, response, and pharmacodynamic effects of decitabine in MDS patients. The authors demonstrate that a low-dose, dose-intensity schedule of decitabine is most effective in achieving optimal epigenetic modulation and clinical responses. This finding holds significant implications for tailoring treatment regimens to individual patients, maximizing therapeutic benefit, and minimizing adverse effects. They also highlight the importance of monitoring epigenetic changes to assess treatment efficacy.

Epigenetic Therapy: A Promising Oasis in the Desert of MDS

This research offers a glimpse into the potential of epigenetic therapy in treating MDS. The authors' findings suggest that optimizing dose and schedule of hypomethylating drugs can significantly improve clinical outcomes. This research serves as a beacon of hope in the ongoing search for effective treatments for MDS, underscoring the importance of personalized medicine and innovative approaches to combat this disease.

Dr.Camel's Conclusion

This research highlights the promise of epigenetic therapy in treating MDS. Optimizing the dose and schedule of decitabine can improve clinical outcomes and epigenetic modulation. The authors' findings offer a ray of hope in the desert of MDS treatment, encouraging further exploration of personalized medicine and innovative therapeutic approaches.
Date :
  1. Date Completed 2007-02-20
  2. Date Revised 2021-02-06
Further Info :

Pubmed ID

16882708

DOI: Digital Object Identifier

10.1182/blood-2006-05-021162

Related Literature

Article Analysis
・Effects of decitabine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.